The fecal microbiota of patients with pancreatic ductal adenocarcinoma and autoimmune pancreatitis characterized by metagenomic sequencing

Zhou, Wenli; De, Zhang; Li, Zhengpeng; Jiang, Huiqing; Li, Jingnan; Ren, Rongrong; Gao, Xuefeng; Li, Jianfeng; Wang, Xin; Wang, Weifeng; Yang, Yunsheng

doi:10.1186/s12967-021-02882-7

Cited by 58 publications

(56 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Histone acetylation and deacetylation have been revealed as important factors for the regulation of cancer progression [ 42 ]. Studies have shown that abnormal histone deacetylation is associated with malignant tumors and HDACi can inhibit cancer progression through remodeling histone acetylation [ 43 ]. Until recently, the inhibitory effect of HDAC1 has been proved in different types of cancer cells, including breast cancer, gastric cancer, pancreatic cancer, non-small cell lung cancer, and colon cancer.…”

Section: Discussionmentioning

confidence: 99%

Anti-Colon Cancer Activity of Novel Peptides Isolated from In Vitro Digestion of Quinoa Protein in Caco-2 Cells

Fan

Guo

Teng

et al. 2022

Foods

View full text Add to dashboard Cite

Quinoa peptides are the bioactive components obtained from quinoa protein digestion, which have been proved to possess various biological activities. However, there are few studies on the anticancer activity of quinoa peptides, and the mechanism has not been clarified. In this study, the novel quinoa peptides were obtained from quinoa protein hydrolysate and identified by liquid chromatography–tandem mass spectrometry (LC–MS/MS). The anticancer activity of these peptides was predicted by PeptideRanker and evaluated using an antiproliferative assay in colon cancer Caco-2 cells. Combined with the result of histone deacetylase 1 (HDAC1) inhibitory activity assay, the highly anticancer activity peptides FHPFPR, NWFPLPR, and HYNPYFPG were screened and further investigated. Molecular docking was used to analyze the binding site between peptides and HDAC1, and results showed that three peptides were bound in the active pocket of HDAC1. Moreover, real-time quantitative polymerase chain reaction (RT-qPCR), and Western blot showed that the expression of HDAC1, NFκB, IL-6, IL-8, Bcl-2 was significantly decreased, whereas caspase3 expression showed a remarkable evaluation. In conclusion, quinoa peptides may have the potential to protect against cancer development by inhibiting HDAC1 activity and regulating the expression of the cancer-related genes, which indicates that these peptides could be explored as functional foods to alleviate colon cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Anti-Colon Cancer Activity of Novel Peptides Isolated from In Vitro Digestion of Quinoa Protein in Caco-2 Cells

Fan

Guo

Teng

et al. 2022

Foods

View full text Add to dashboard Cite

show abstract

“…Some microbes are more abundant in Pancreatic Ductal Adeno Carcinoma (PDAC) patients including Klebsiella pneumoniae, Clostridium bolteae, S. mutans, and Parabacteroides spp., Acinetobacter, and Pseudomonas (Thomas and Jobin, 2020;Lau et al, 2021;Matsukawa et al, 2021). The abundance of other microbes such as Firmicutes is significantly lower in PDAC patients (Lau et al, 2021;Zhou et al, 2021). Most PDAC patients suffer from a leaky gut which results in the translocation of harmful bacteria into the bloodstream (Wu et al, 2014).…”

Section: Microbiome Implications In the Development Of Malignant Tumorsmentioning

confidence: 99%

Recent Advances in Understanding the Structure and Function of the Human Microbiome

2022

View full text Add to dashboard Cite

Trillions of microbes live within our bodies in a deep symbiotic relationship. Microbial populations vary across body sites, driven by differences in the environment, immunological factors, and interactions between microbial species. Major advances in genome sequencing enable a better understanding of microbiome composition. However, most of the microbial taxa and species of the human microbiome are still unknown. Without revealing the identity of these microbes as a first step, we cannot appreciate their role in human health and diseases. A shift in the microbial balance, termed dysbiosis, is linked to a broad range of diseases from simple colitis and indigestion to cancer and dementia. The last decade has witnessed an explosion in microbiome research that led to a better understanding of the microbiome structure and function. This understanding leads to potential opportunities to develop next-generation microbiome-based drugs and diagnostic biomarkers. However, our understanding is limited given the highly personalized nature of the microbiome and its complex and multidirectional interactions with the host. In this review, we discuss: (1) our current knowledge of microbiome structure and factors that shape the microbial composition, (2) recent associations between microbiome dysbiosis and diseases, and (3) opportunities of new microbiome-based therapeutics. We analyze common themes, promises, gaps, and challenges of the microbiome research.

show abstract

“…The microbiota could also play a role as a potential biomarker in the differential diagnosis of pathologies that can mimic PDAC, such as autoimmune pancreatitis [78]. When analyzing the microbiota of patients with adenocarcinoma and autoimmune pancreatitis, Zhou et al found a significant difference in bacterial types and fecal butyrate content [79]. In patients with PDAC, there was a large decrease in Firmicutes (mainly butyrate-producing bacteria), and an increase in Proteobacteria (mainly Gammaproteobacteria).…”

Section: Gut Microbiota and Intratumor Microbiota In Pdacmentioning

confidence: 99%

Microbiota in Pancreatic Diseases: A Review of the Literature

Schepis

Lucia

Nista

et al. 2021

JCM

View full text Add to dashboard Cite

The gut microbiota is a critical element in the balance between human health and disease. Its impairment, defined as dysbiosis, is associated with gastroenterological and systemic diseases. Pancreatic secretions are involved in the composition and changes of the gut microbiota, and the gut microbiota may colonize the pancreatic parenchyma and be associated with the occurrence of diseases. The gut microbiota and the pancreas influence each other, resulting in a “gut microbiota-pancreas axis”. Moreover, the gut microbiota may be involved in pancreatic diseases, both through direct bacterial colonization and an indirect effect of small molecules and toxins derived from dysbiosis. Pancreatic diseases such as acute pancreatitis, chronic pancreatitis, autoimmune pancreatitis, and pancreatic cancer are common gastroenterological diseases associated with high morbidity and mortality. The involvement of the microbiota in pancreatic diseases is increasingly recognized. Therefore, modifying the intestinal bacterial flora could have important therapeutic implications on these pathologies. The aim of this study is to review the literature to evaluate the alterations of the gut microbiota in pancreatic diseases, and the role of the microbiota in the treatment of these diseases.

show abstract

The fecal microbiota of patients with pancreatic ductal adenocarcinoma and autoimmune pancreatitis characterized by metagenomic sequencing

Cited by 58 publications

References 43 publications

Anti-Colon Cancer Activity of Novel Peptides Isolated from In Vitro Digestion of Quinoa Protein in Caco-2 Cells

Anti-Colon Cancer Activity of Novel Peptides Isolated from In Vitro Digestion of Quinoa Protein in Caco-2 Cells

Recent Advances in Understanding the Structure and Function of the Human Microbiome

Microbiota in Pancreatic Diseases: A Review of the Literature

Contact Info

Product

Resources

About